ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2385

High Incidence of Hepatitis Related to HBV Reactivation in Rheumatoid Arthritis Patients with Resolved Hepatitis B Infection during Rituximab Treatment

Ming-Han Chen1, Yen-Po Tsao2, Yi-Hsiang Huang3, Chung-Tei Chou4 and Chang Youh Tsai2, 1Division of Allergy- Immunology- Rheumatology, Department of Medicine, Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 2Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 3Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 4Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Hepatitis, rheumatoid arthritis (RA) and rituximab

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Session Title: Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Abstract

Background/Purpose: Rituximab-based chemotherapy can induce hepatitis B virus (HBV) reactivation (HBVr) in patients with hematological malignancies who have been exposed to HBV infection. However, informative data regarding the risk of Rituximab on HBVr among patients with rheumatoid arthritis (RA) is unsettled.

Methods: We retrospectively reviewed RA patients in Taipei Veterans General Hospital and patients with available HBV markers before rituximab administration were enrolled. HBVr was defined as either an increase in HBV DNA >1 Log10 IU/ml compared with baseline or threefold increase in serum alanine aminotransferase (ALT) level accompanied with HBV DNA > 20,000 IU/mL in cases without baseline HBV viral load, or hepatitis B surface antigen (HBsAg) reverse seroconversion in HBsAg-negative cases.

Results: Eighty-eight patients were enrolled; 83 (94.3%) were female and the mean age at diagnosis was 54.2 years (Table 1). They received a median of 9 cycles of RTX (range 1-20) without anti-HBV prophylaxis. Four patients were positive for hepatitis B surface antigen (HBsAg) before rituximab administration (Figure 1). In 84 HBsAg-negative patients, 46 were positive for anti-hepatitis B core antigen (anti-HBc), 19 were negative for anti-HBc, and 19 did not have anti-HBc data. Among 46 HBsAg-negative/anti-HBc-positive patients, 31 were hepatitis B surface antibody (anti-HBs)-positive, 6 were anti-HBs-negative, and 9 did not have anti-HBs data. During 10,877 person-months of follow-up, 5 (5.7%) patients developed HBVr. HBVr occurred in 2 (50.0%) of 4 HBsAg-positive patients and the time to HBVr was 40 and 74 months after the start of rituximab, respectively. Among 31 HBsAg-negative/anti-HBc-positive/anti-HBs-positive patients, a decrease in anti-HBs levels was observed in 21 (67.7%) cases after rituximab treatment and anti-HBs disappeared in 6 (19.4%) patients. Three (50.0%) of anti-HBs-disappear patients seroreverted to HBsAg-positive and all of them developed HBVr later with the mean time from the start of rituximab to HBVr was 59.3 months (range 56-62months).

Conclusion: HBVr is common in HBsAg-positive RA patients under rituximab therapy. More importantly, rituximab may lead to high disappearance rate of anti-HBs in resolved HBV cases, resulting in high risk of HBVr. Monitor HBV status frequently is critical in RA patients who have been exposed to HBV infection during rituximab treatment.

´y­z: C:\Users\mhchen6\Dropbox\¬ã¨s\RTX in VGHTPE\ACR\·s¼W Microsoft PowerPoint ²³ø\table1.JPG

´y­z: C:\Users\mhchen6\Dropbox\¬ã¨s\RTX in VGHTPE\ACR\·s¼W Microsoft PowerPoint ²³ø\Fig2.JPG


Disclosure: M. H. Chen, None; Y. P. Tsao, None; Y. H. Huang, None; C. T. Chou, None; C. Y. Tsai, None.

To cite this abstract in AMA style:

Chen MH, Tsao YP, Huang YH, Chou CT, Tsai CY. High Incidence of Hepatitis Related to HBV Reactivation in Rheumatoid Arthritis Patients with Resolved Hepatitis B Infection during Rituximab Treatment [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/high-incidence-of-hepatitis-related-to-hbv-reactivation-in-rheumatoid-arthritis-patients-with-resolved-hepatitis-b-infection-during-rituximab-treatment/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-incidence-of-hepatitis-related-to-hbv-reactivation-in-rheumatoid-arthritis-patients-with-resolved-hepatitis-b-infection-during-rituximab-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences